Valeant Pharma (VRX) Reports Q3 EPS of $2.11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Valeant Pharmaceuticals (VRX) PT, Estimates Raised at Jefferies on Strong Q3
October 21, 2014 8:00 AM EDTJefferies analyst David Steinberg reiterated a Buy rating and boosted his price target on Valeant Pharmaceuticals (NYSE: VRX) to $149.00 (from $141.00) following strong Q3 results.
Steinberg commented, "Valeant reported a strong Q3 as expected. While revs of $2.06B were slightly dampened due... More
Valeant Pharma (VRX) Posts Strong Q3 Results, Bumps Outlook Higher; Aegis Capital Maintains at 'Buy'
October 20, 2014 9:55 AM EDTAegis Capital affirms its Buy rating and $180 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q3 results and guidance update.
Analyst Ram Selvaraju commented, This morning, Valeant reported third quarter 2014 financial results. The firm delivered cash EPS of $2.11 per share vs. our projection of... More
